Working in league with the Massachusetts General Hospital (MGH) Diabetes Research Center, Samsung is testing how wearables like the Galaxy Watch 8 can help prevent critical muscle loss spurred by the use of GLP-1 weight-loss drugs. The goal is to investigate the feasibility of using biometric and body composition data, collected by smart wearables, to manage GLP-1 muscle loss. To understand why this is promising and why it matters, we have to back up a little. While GLP-1s like Ozempic and Wegovy have been successfully helping people manage their diabetes and weight loss, we still don't have enough data on the long-term effects of using these drugs. A KFF poll reveals that about one in every five adults have taken a GLP-1 drug to help with a health condition. That's a lot of people — and the use of GLP-1s, in general, has quadrupled since 2021. Naturally, we might want to learn more about residual use. It's even more relevant with the discovery of new natural alternatives to Ozempic and similar GLP-1s.…